Processa (PCSA) Amends Form 4, Confirms CEO Holdings and $0.65 Warrants

Rhea-AI Filing Summary

Processa Pharmaceuticals (PCSA) reporting person George K. Ng amended a prior Form 4 to correct an earlier filing error. The amendment shows Mr. Ng is both a director and the Chief Executive Officer. The filing discloses indirect beneficial ownership of 87,200 shares of common stock held through warrants and 20,000 shares held by the Ng Cha Family Trust, as well as separate warrant holdings converting into 87,200 and 43,600 common shares at a $0.65 exercise price expiring 01/29/2030. The earliest transaction date listed is 07/24/2025, and the amendment notes the prior Form 4 was filed in error.

Positive

• Amendment corrects prior filing, improving disclosure accuracy
• Confirms CEO and director beneficial ownership, adding transparency
• Provides clear warrant terms: $0.65 exercise price, 01/29/2030 expiration

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine correction of an insider filing; confirms CEO/director holdings and fixes prior reporting error.

The amendment clarifies the reporting record by retracting an earlier erroneous Form 4 and restating beneficial ownership positions. Disclosure of indirect holdings through trusts and IRRAs is standard; the filing enhances transparency about executive ownership. There is no new grant or disposition reported here, only correction and affirmation of existing warrant and share positions.

Securities Analyst

TL;DR: Neutral impact—confirms strike price and expiration of warrants and total indirect share counts, with no apparent material transfer.

The Form 4/A lists warrants exercisable at $0.65 expiring 01/29/2030 and shows 87,200 and 43,600 underlying shares tied to the reporting person via an IRRA. It also reports 20,000 shares held by a family trust. Because the filing is an amendment to correct a prior error rather than a new economic transaction, it is informational rather than market-moving.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Ng George K

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FL 32960

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
07/28/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								87,200	I	George Ng IRRA FBO: George Ng
Common Stock								20,000	I	Ng Cha Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Warrants	$0.65							01/29/2025	01/29/2030	Common Stock	87,200		87,200	I	George Ng IRRA FBO: George Ng
Warrants	$0.65							01/29/2025	01/29/2030	Common Stock	43,600		43,600	I	George Ng IRRA FBO: George Ng

Explanation of Responses:

Remarks:

Amendment filed to retract the prior Form 4, which was filed in error.

	/s/ George Ng, by John J. Wolfel, as Attorney-in-Fact	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4/A for Processa Pharmaceuticals (PCSA) disclose?

The amendment discloses that reporting person George K. Ng indirectly beneficially owns 87,200 shares 20,000 shares; it also lists additional warrants for 43,600 shares.

Why was this Form 4 amended for PCSA?

The form states an amendment was filed to retract the prior Form 4, which was filed in error.

What are the warrant terms disclosed in the filing?

The warrants have a $0.65 exercise price and an expiration date of 01/29/2030.

What roles does the reporting person hold at Processa Pharmaceuticals?

George K. Ng is disclosed as both a Director and the company’s Chief Executive Officer.

When is the earliest transaction date listed on the Form 4/A?

The earliest transaction date shown is 07/24/2025.